Workflow
Gilead Sciences (GILD) Tops Q4 Earnings and Revenue Estimates
GILDGilead(GILD) ZACKS·2025-02-11 23:12

Group 1 - Gilead Sciences reported quarterly earnings of 1.90pershare,exceedingtheZacksConsensusEstimateof1.90 per share, exceeding the Zacks Consensus Estimate of 1.67 per share, and showing an increase from 1.72pershareayearago,representinganearningssurpriseof13.771.72 per share a year ago, representing an earnings surprise of 13.77% [1] - The company achieved revenues of 7.57 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 7.27%, and an increase from 7.12billionyear−over−year[2]−GileadhasconsistentlyoutperformedconsensusEPSandrevenueestimatesoverthelastfourquarters[2]Group2−Thestock′simmediatepricemovementwilldependonmanagement′scommentaryduringtheearningscallandfutureearningsexpectations[3]−Gileadshareshaveincreasedbyapproximately3.47.12 billion year-over-year [2] - Gilead has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Group 2 - The stock's immediate price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - Gilead shares have increased by approximately 3.4% since the beginning of the year, compared to a 3.1% gain in the S&P 500 [3] Group 3 - The current consensus EPS estimate for the upcoming quarter is 1.82 on revenues of 6.66billion,andforthecurrentfiscalyear,itis6.66 billion, and for the current fiscal year, it is 7.59 on revenues of $28.27 billion [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 26% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]